-

Master Raw Material Compliance in Pharmaceuticals Course: Focus on Health Canada, USP & EP Standards - 2-Day Virtual Seminar (Nov 20th - Nov 21st, 2025) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Master Raw Material Compliance in Pharmaceuticals: Health Canada, USP & EP Standards - 2-Day Virtual Seminar (Nov 20th - Nov 21st, 2025)" training has been added to ResearchAndMarkets.com's offering.

Ensure your pharmaceutical operations meet the highest regulatory standards with our 2-Day Virtual Seminar on Raw Material Compliance in Pharmaceuticals. This comprehensive course covers critical requirements from Health Canada, USP, and EP standards, focusing on practical strategies to manage raw material sourcing, testing, and documentation.

Every biotech product is an amalgam of multiple raw materials that add purpose and efficiency to it. Since raw materials are the foundation of these products, it is important to have regulatory norms in place for them. Hence, this seminar discusses raw material compliance to ensure every final product meets FDA expectations and guidelines.

We have enforced the idea of good manufacturing practices through several pharmaceutical GMP training programs. However, minute elements like raw materials need critical attention to avoid warning letters.

The world compliance seminars team has come up with a detailed course on raw material compliance to understand the intricacy of an ingredient in a product.

Course Overview

Did you know more than 5000 firms received the notice for not having cGMP-controlled raw materials? This is not a scenario you dream of while running a pharmaceutical and biotech manufacturing business.

As much as the cGMP course plays an essential role, concerned personnel needs to understand regulatory requirements for raw materials. The basic framework of this course is different from cGMP online training.

It includes topics like testing and approval of the raw materials, rejection criteria of components, product container management, and closures.

As far as the benefits of pharmaceutical cGMP training are concerned, you will learn the following things:

  • Basic guidelines to formulate representative samples for effective testing and inspection
  • Best practices to release each component, packaged product, and closures
  • Appropriate techniques to collect samples alongside preventing contamination, maintaining sterility in equipment, and aseptic processing
  • General criteria for testing and examination of the samples
  • Impact of multiple raw materials on the end user
  • Adhere to the best practices required for commercial-grade manufacturing

In addition to these general topics, here are the topics that will be discussed in the seminar.

Who Should Attend:

Raw material compliance is currently the talk of the town and upskilling yourself will help you in building a positive career. Moreover, additional knowledge of cGMP violations will help you excel in the department.

Below are some professionals who will benefit from this FDA compliance training:

  • Regulatory and Compliance Professionals: Develop the ability to identify loopholes and build a better system for raw material procurement and processing.
  • Manufacturing and Quality Engineers: Assess the quality of the product internally and set a benchmark for the entire team to avoid warning letters and product recalls.
  • Document Control Specialists: Gain perspective on documenting the characteristics of the raw material appropriately for future reference.
  • Quality Auditors: In-house auditors play an essential role in product examination and are responsible for giving critical feedback on the entire system.
  • Project Managers: The course will help them understand basic regulations related to raw materials so they can take suitable action and manage product development.

Key Topics Covered:

DAY 01 - Regulatory Frameworks & Raw Material Impact

  • Compare and contrast FDA, Health Canada, ICH, USP, and EP regulatory requirements
  • Explore various raw materials and their impact on product quality and patient safety
  • Understand the role of raw materials in the timely production of pharmaceutical products
  • Deep dive into the impact of the most commonly used raw material in large molecule production and its user implications
  • Review regulatory requirements from Phase 1 to Commercial Manufacturing
  • Discuss the role and limitations of Certificates of Analysis (CoA) vs. additional testing requirements

DAY 02 - Testing Strategies & Risk Management

  • Evaluate the use of compendial vs. non-compendial testing - benefits and limitations
  • Understand regulatory risk management (ICH Q9) related to raw materials
  • Learn best practices for sampling strategies and testing methods
  • Explore the impact of ASQ (American Society for Quality) principles and the ?(N+1) approach in determining sample size and attribute testing
  • Apply concepts through practical case studies
  • Analyze real-world Warning Letter examples to highlight compliance challenges

Speakers:

Barry A. Friedman, Ph.D

Consultant

Cambrex Bio Sciences

Dr. Friedman possesses over 30 years of industrial managerial experience in various aspects of biopharmaceuticals and medical devices to include regulatory compliance, expert witness testimony, GLP/GMP, quality control, auditing, sterility assurance, microbiological/analytical validations and fermentation technology.

Prior to becoming an independent consultant, Dr. Friedman was associated with Cambrex Bio Sciences, a contract manufacturer of GMP bulk biopharmaceuticals located in Baltimore, Maryland. As the Director of Quality Control, he managed a multi-shift Department of thirty one individuals involved in client management, the receipt and testing of raw materials, environmental monitoring and microbiology, analytical chemistry and QC compliance for the production of Phase 1, 2, 3 and commercial products manufactured from bacteria, yeast and mammalian cells. In this capacity, Dr Friedman enjoyed many client and regulatory interactions, both domestic and international.

Prior to 2000, Dr. Friedman was the Laboratory Director for Chesapeake Biological Laboratories, a contract Aseptic Fill n' Finish manufacturer located in Baltimore, Maryland. In addition to the professional history listed above, other associations have included W.R. Grace, Sigma Chemical Co., Sherwood Medical, Becton Dickinson, American Cyanamid and Union Carbide.

Dr. Friedman received his B.S. degree in Microbiology from Ohio State University, his M.S. from Michigan State University in Microbial Genetics, and his PhD from Ohio State University in Microbiology.

For more information about this training visit https://www.researchandmarkets.com/r/7qzn2y

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Poland Investment Funds and Asset Management Market Report 2026, Profiles of TFI, Pekao, Santander, PKO, Allianz, Goldman Sachs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investment Funds and Asset Management Market in Poland, 2024-2026" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive overview of the investment funds and asset management sector in Poland. Analysis covers the main pillars of the market, including: mutual funds, insurance, and pension assets. The report also mid-term forecast of key volumes for the period 2025-2027. The data has been presented in a form of horizontal pr...

Europe Data Center Colocation Market Outlook & Forecast Report 2025-2030 Featuring Major Players - Digital Realty, Equinix, NTT DATA, Global Switch, CyrusOne, Ark Data Centres - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Europe Data Center Colocation Market - Industry Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Europe Data Center Colocation Market was valued at USD 9.45 Billion in 2024, and is projected to reach USD 35.73 Billion by 2030, rising at a CAGR of 24.82%. The Europe data center colocation market is expected to witness cumulative investments of approximately $144.03 billion, of which, the Western Europe is slated to ac...

GCC Construction Equipment Market Research Report 2025-2030 Featuring Key Vendors - Caterpillar, Komatsu, Volvo, Hitachi, SANY, XCMG, JCB, Liebherr, Kobelco, and Zoomlion - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "GCC Construction Equipment Market Research Report 2025-2030" report has been added to ResearchAndMarkets.com's offering. The GCC Construction Equipment Market was sized at 68,499 Units in 2024, and is projected to reach 94,499 Units by 2030, rising at a CAGR of 5.51%. Governments in the UAE and Saudi Arabia continue to prioritize urban growth and diversification, with Dubai's long-term 2040 Urban Master Plan and the Saudi Vision 2030-linked mega-projects fuelling o...
Back to Newsroom